179 related articles for article (PubMed ID: 29480865)
1. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.
Jin J; Zheng C; Wu S
Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865
[TBL] [Abstract][Full Text] [Related]
2. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
3. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
[TBL] [Abstract][Full Text] [Related]
7. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
[TBL] [Abstract][Full Text] [Related]
8. Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.
Yang D; Zhang WP; Yang JM; He MX; Cheng C; Chen J
Medicine (Baltimore); 2018 Dec; 97(49):e13093. PubMed ID: 30544372
[TBL] [Abstract][Full Text] [Related]
9. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Lun Y; Yang JJ; Wu Y
J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
[TBL] [Abstract][Full Text] [Related]
10. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.
Li L; Wu C; Chai Y; Dong C; Zhao L
Int J Immunopathol Pharmacol; 2021; 35():20587384211009342. PubMed ID: 33845613
[TBL] [Abstract][Full Text] [Related]
11. Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT.
Zhang N; Zhang S; Ma L; Qiu L; Meng QL; Cai J; Xu Z; Yao H; Fan FY
Medicine (Baltimore); 2023 Oct; 102(40):e35413. PubMed ID: 37800816
[TBL] [Abstract][Full Text] [Related]
12. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
[TBL] [Abstract][Full Text] [Related]
13. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
[TBL] [Abstract][Full Text] [Related]
14. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
Hu S; Zou D; Zhou D; Zhang Y; Wang W; Zhang W
Medicine (Baltimore); 2020 Oct; 99(43):e22788. PubMed ID: 33120793
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.
Wu P; Ma T; Chen Y; Wang F; Chen Y; Gao J; Zhou Z; Jia Y
Anticancer Drugs; 2021 Sep; 32(8):886-889. PubMed ID: 34145178
[TBL] [Abstract][Full Text] [Related]
17. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of relapsed and refractory EZB/C3 subtype DLBCL with chidamide in combination of R2-CHOP: a case report].
Yang L; Zhang W; Zhang ML; Shen KF; Wang JC; Guan YQ; Cai HD; Bao YH; Xiao M; Zhou JF; Zheng M
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):436-437. PubMed ID: 34218590
[No Abstract] [Full Text] [Related]
19. [Chidamide combined with chemotherapy for treatment of therapy-related acute myeloid leukemia secondary to peripheral T-cell lymphoma: a case report and literatures review].
Wu RJ; Zheng RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):685-687. PubMed ID: 31495139
[No Abstract] [Full Text] [Related]
20. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
